Valuation : Insmed Incorporated

Market Cap 27.66B 23.8B 22.34B 20.44B 38.14B 2,615B 38.45B 264B 103B 1,336B 104B 102B 4,304B P/E 2026 *
-77.5x
P/E 2027 * 141x
Enterprise Value 27.03B 23.26B 21.83B 19.97B 37.27B 2,555B 37.57B 258B 101B 1,306B 102B 99.3B 4,206B EV / Sales 2026 *
15x
EV / Sales 2027 * 9.19x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+4.36%
Current month+3.99%
1 month+28.67%
3 months+21.97%
6 months-13.82%
Current year-27.21%
1 week 117.51
Extreme 117.51
127.09
1 month 98.64
Extreme 98.64
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
8/6/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+4.36%-11.72%+459.54% 27.66B
+0.41%-2.07%+41.26%+95.40% 69.02B
-1.53%+0.40%+42.35%+89.26% 66.32B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-0.27%+1.48%+25.39%-17.84% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
-0.79%-0.20%+24.66%+193.08% 12.54B
Average -0.30%-1.26%+44.61%+189.31% 29.58B
Weighted average by Cap. -0.45%-0.81%+40.80%+150.01%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.46B 1.33B 2.49B 171B 2.51B 17.25B 6.72B 87.26B 6.78B 6.64B 281B 2.89B 2.48B 2.33B 2.13B 3.98B 273B 4.01B 27.57B 10.73B 139B 10.84B 10.6B 449B
Net income -349M -301M -282M -258M -482M -33.03B -486M -3.34B -1.3B -16.88B -1.31B -1.28B -54.36B 211M 182M 171M 156M 292M 19.99B 294M 2.02B 786M 10.21B 794M 777M 32.9B
Net Debt -632M -544M -510M -467M -871M -59.73B -878M -6.03B -2.35B -30.52B -2.37B -2.32B -98.3B -1.16B -995M -934M -854M -1.59B -109B -1.61B -11.05B -4.3B -55.87B -4.34B -4.25B -180B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-09-04 US$126.41 -0.21% 86,620
26-09-03 US$126.68 +0.04% 1,885,698
26-09-02 US$126.63 +4.21% 1,998,834
26-09-01 US$121.51 -0.25% 1,419,286
26-08-31 US$121.82 +2.77% 2,390,325
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
126.68USD
Average target price
200.18USD
Spread / Average Target
+58.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock